Safety and use of pegylated carboxyhemoglobin bovine in patients with low hemoglobin level

Trial Profile

Safety and use of pegylated carboxyhemoglobin bovine in patients with low hemoglobin level

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs PEG-haemoglobin carbon monoxide (Primary)
  • Indications Acute myeloid leukaemia; Haemorrhagic shock; Sickle cell anaemia; Wounds and injuries
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top